CORDIS
EU research results

CORDIS

English EN
Fast tracking market adoption of a novel immune-based diagnostic for improving antibiotic stewardship: automation, piloting and health economics

Fast tracking market adoption of a novel immune-based diagnostic for improving antibiotic stewardship: automation, piloting and health economics

Objective

MeMed has completed development of ImmunoXpert™, an in vitro diagnostic test that leverages the body’s immune system to accurately differentiate between bacterial and viral infections. A breakthrough in infectious disease diagnosis, ImmunoXpert™ overcomes limitations of traditional diagnostics, outperforming standard of care. ImmunoXpert™ recently received regulatory European clearance (CE-IVD) and represents a close-to-market innovation. Market entry points include emergency department and hospitalized pediatric patients with respiratory tract infections (RTI) and fever without source (FWS), for which ImmunoXpert™ is uniquely positioned to improve patient management and health economics. In children, RTIs account for 50% of doctor visits and hospitalization. Fever accounts for 10-25% of pediatric ED visits, with as many as 20% without identifiable source. The global market for ImmunoXpert™ diagnosis of pediatric RTI/FWS is €2.8B (EU is €560M).
To fast track market adoption across Europe we propose:
•To transition ImmunoXpert™ from a hands-on laboratory assay to Tecan’s hands-free, rapid automated laboratory platform to increase clinical utility and economic benefit
•To roll-out ImmunoXpert™ to EU pilot hospitals with the goal of managing 1200 pediatric patients to evaluate performance and clinical utility in real working conditions
•To perform health economics analysis and establish reimbursement strategy

AutoPilot-Dx is a cross sector effort (industry, KOLs, outcome researchers) highly aligned with H2020-FTIPilot’s goals and Societal Challenges: it will reduce ImmunoXpert™’s time to market and provide a road-map for sustainable market uptake; a H2020 first-time applicant is involved; the project will enable MeMed and Tecan to scale-up in line with their business strategies; the immune-based diagnostics will improve antibiotic stewardship, providing better, personalized, care for children with RTI/FWS and help fight antibiotic resistance – a global health threat
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

MEMED DIAGNOSTICS LTD

Address

Nahum Heth Street 5
39120 Tirat Carmel

Israel

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 655 025

Participants (5)

Sort alphabetically

Sort by EU Contribution

Expand all

QUANTIFY RESEARCH AB

Sweden

EU Contribution

€ 437 500

TECAN DEUTSCHLAND GMBH

Germany

EU Contribution

€ 370 125

UNIVERSITA DEGLI STUDI DI MILANO

Italy

EU Contribution

€ 26 937,50

RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG

Germany

EU Contribution

€ 415 625

UNIVERSITA DEGLI STUDI DI PERUGIA

Italy

EU Contribution

€ 388 687,50

Project information

Grant agreement ID: 701088

Status

Ongoing project

  • Start date

    1 September 2016

  • End date

    31 August 2019

Funded under:

H2020-EU.3.

H2020-EU.2.

  • Overall budget:

    € 2 923 250

  • EU contribution

    € 2 293 900

Coordinated by:

MEMED DIAGNOSTICS LTD

Israel